Triple-negative breast cancer (TNBC) is an exclusive pathological subtype with negative estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (Her-2), which leads to the sum of diseases with high heterogeneity and plasticity. TNBC has the aggressive characteristics of short overall survival, high degree of malignancy, strong invasive ability, and high early recurrence rate.
In recent studies, TNBC was shown to be immune-activated, suggesting that immunotherapy may be a viable treatment strategy. Indeed, immunotherapy was evaluated and has been approved for TNBC clinical trials. Evaluation of immune targets and adaptive immunity-related cell populations suggests that “immune hot” TNBC is the best potential candidate for immune checkpoint blockers. Yet the complex interactions among tumor cells, stromal cells, and immune cells in TNBC are not completely understood. The metabolism of immune cells in?uences their differentiation and function; hence, metabolic reprogramming may provide promising therapeutic targets for the treatment of TNBC.
This research topic aims to provide insight into the clinical and molecular profile of immunotherapy in TNBC, including immunotherapy biomarkers, immune checkpoint inhibitors, immunomodulatory antibodies, tumor-infiltrating lymphocytes, cytokines, metabolic changes, and clinical outcomes. We will focus on how genetic alterations influence the composition of immune cells present in the tumor microenvironment. This topic will include physical mechanisms in tumor metabolic reprogramming and link these changes to targetable molecular mechanisms, which will facilitate the generation of new physical sciences-inspired insights for clinical translation. Furthermore, it will contribute to a fundamental understanding of the microenvironment in TNBC, to the identification of potential biomarkers, and will aid in the design and interpretation of clinical trials.
Potential topics include but are not limited to the following,
• Immunotherapy biomarkers
• Immune checkpoint inhibitors
• Immunomodulatory antibodies
• Tumor-infiltrating lymphocytes
• Immunotherapy and combination treatments
• Glucose metabolism FA metabolism amino acids
• Relevant metabolic reprogramming target genes and pathways
• Oncogenic regulators of metabolism
• Metabolic feedback effects and stress responses
Please note that all the above-mentioned topics should pertain to TNBC.
Please note additionally: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied and will not be accepted as part of this Research Topic.
Triple-negative breast cancer (TNBC) is an exclusive pathological subtype with negative estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (Her-2), which leads to the sum of diseases with high heterogeneity and plasticity. TNBC has the aggressive characteristics of short overall survival, high degree of malignancy, strong invasive ability, and high early recurrence rate.
In recent studies, TNBC was shown to be immune-activated, suggesting that immunotherapy may be a viable treatment strategy. Indeed, immunotherapy was evaluated and has been approved for TNBC clinical trials. Evaluation of immune targets and adaptive immunity-related cell populations suggests that “immune hot” TNBC is the best potential candidate for immune checkpoint blockers. Yet the complex interactions among tumor cells, stromal cells, and immune cells in TNBC are not completely understood. The metabolism of immune cells in?uences their differentiation and function; hence, metabolic reprogramming may provide promising therapeutic targets for the treatment of TNBC.
This research topic aims to provide insight into the clinical and molecular profile of immunotherapy in TNBC, including immunotherapy biomarkers, immune checkpoint inhibitors, immunomodulatory antibodies, tumor-infiltrating lymphocytes, cytokines, metabolic changes, and clinical outcomes. We will focus on how genetic alterations influence the composition of immune cells present in the tumor microenvironment. This topic will include physical mechanisms in tumor metabolic reprogramming and link these changes to targetable molecular mechanisms, which will facilitate the generation of new physical sciences-inspired insights for clinical translation. Furthermore, it will contribute to a fundamental understanding of the microenvironment in TNBC, to the identification of potential biomarkers, and will aid in the design and interpretation of clinical trials.
Potential topics include but are not limited to the following,
• Immunotherapy biomarkers
• Immune checkpoint inhibitors
• Immunomodulatory antibodies
• Tumor-infiltrating lymphocytes
• Immunotherapy and combination treatments
• Glucose metabolism FA metabolism amino acids
• Relevant metabolic reprogramming target genes and pathways
• Oncogenic regulators of metabolism
• Metabolic feedback effects and stress responses
Please note that all the above-mentioned topics should pertain to TNBC.
Please note additionally: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied and will not be accepted as part of this Research Topic.
